NCT01684163已完成2 期
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Naurex, Inc, an affiliate of Allergan plc22 个研究点 分布在 1 个国家目标入组 369 人开始时间: 2012年11月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 369
- 试验地点
- 22
- 主要终点
- Change in Hamilton Depression Rating Scale Score
研究概览
简要总结
GLYX-13 is a NMDA receptor glycine site partial agonist being studied in subjects with major depressive disorder (depression) who have responded inadequately to another antidepressant drug during the current episode. This trial will assess the effects of GLYX-13 on depression when added to another antidepressant drug that the patient is already taking.
详细描述
To evaluate the mean difference in Hamilton Depression Rating Scale 17 (HDRS-17) score for the combined GLYX-13 mean change versus the placebo group mean change at the end of a 6 week randomized withdrawal phase (predose baseline score - score at end of randomized withdrawal period).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female subjects
- •Aged 18 to 65 years
- •Meets DSM-IV-TR) criteria for major depressive disorder (MDD)
- •Current episode has lasted ≥ 8 weeks before Screening with an inadequate response to all approved antidepressant agent(s) administered at an adequate dose and duration for the current episode
- •Taking no antidepressant agent currently or taking an SSRI or SNRI
- •HDRS-17 score ≥ 18 at screening and predose baseline
- •Female subjects of childbearing potential with a negative serum pregnancy test prior to entry into the study and who are practicing an adequate method of birth control and who do not plan to become pregnant during the course of the study.
- •Clinical laboratory values < 2 times the upper limit of normal (ULN) or deemed not clinically significant per the investigator and Naurex medical monitor
- •Ability to understand the requirements of the study, provide written informed consent, abide by the study restrictions, and agree to return for the required assessments
- •Based on the investigator and Naurex medical monitor's clinical judgment, subjects with eating disorders, obsessive compulsive disorder (OCD), panic disorder, post-traumatic stress disorder (PTSD), and generalized anxiety disorders secondary to major depressive episodes (MDEs) are permitted.
排除标准
- •Axis I diagnosis of delirium, dementia, dysthymia, amnestic or other cognitive disorder, schizophrenia or other psychotic disorder, bipolar I or II disorder, eating disorder (anorexia or bulimia nervosa), obsessive-compulsive disorder, panic disorder, acute stress disorder, agoraphobia, social phobia, attention-deficit hyperactivity disorder (ADHD), or PTSD
- •A clinically significant current Axis II diagnosis of borderline, antisocial, paranoid, schizoid, schizotypal, or histrionic personality disorder
- •Experiencing hallucinations, delusions, or any psychotic symptomatology in the current episode; lifetime history of psychosis
- •Huntington's, Parkinson's, Alzheimer's, Multiple Sclerosis, or a history of seizures or strokes
- •Currently hospitalized or residing in an in-patient facility during the study participation
- •Substance abuse within the last 12 months
- •Women who are planning to become pregnant during the course of the study
- •Allergy or intolerance to current antidepressant or other current medications
- •Participation in any clinical trial of an investigational product or device within 30 days of enrollment in this trial with the exception of GLYX13-C-
- •Positive screen for drugs of abuse
- •Have received electroconvulsive therapy, transcranial magnetic stimulation (TMS), or vagal nerve stimulation (VNS) for the current depressive episode
- •Pose current (past 6 months) suicide risk based on administration of the C SSRS and the investigator's clinical judgment
- •Human immunodeficiency virus (HIV) infection (based on the HIV-1 & HIV-2 antibody screen) or other ongoing infectious disease
- •Females who are currently pregnant or planning to become pregnant during the course of the study
- •Dextromethorphan or tramadol since these are serotonin uptake inhibitors
- •History of allergy, sensitivity, or intolerance to N-methyl-D-aspartate receptor [NMDAR] ligands
研究组 & 干预措施
Placebo injection
Placebo Comparator
Normal saline
干预措施: Placebo (Drug)
GLYX-13, 5 mg/kg
Experimental
Low dose of GLYX-13
干预措施: GLYX-13 5 mg/kg (Drug)
GLYX-13, 10 mg/kg
Experimental
High dose of GLYX-13
干预措施: GLYX-13 10 mg/kg (Drug)
结局指标
主要结局
Change in Hamilton Depression Rating Scale Score
时间窗: 6 weeks, 12 weeks, 16 weeks
次要结局
- Clinical Global Impression of Change(6 weeks, 12 weeks, 16 weeks)
研究者
研究点 (22)
Loading locations...
相似试验
已完成
2 期
Single IV Dose of GLYX-13 in Patients With Treatment-Resistant DepressionMajor Depressive DisorderNCT01234558Naurex, Inc, an affiliate of Allergan plc115
已完成
2 期
Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid AlcoholismSchizophreniaAlcoholismNCT00338598Yale University20
已完成
2 期
A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive DisorderAdjunctive Treatment of Major Depressive Disorder (MDD)NCT06340958Clexio Biosciences Ltd.99
终止
2 期
A Study of GW856553X For the Treatment of DepressionDepressive Disorder, MajorNCT00569062GlaxoSmithKline30
终止
2 期
Study of Depression-Ketamine-Brain FunctionMajor DepressionNCT01135758Markus KOSEL10